**TABLE, SUPPLEMENTAL DIGITAL CONTENT 2.** BCVA, Corneal Fluorescein Staining and Intraocular Pressure in a Study of Lifitegrast Compared With Placebo for Dry Eye Disease

|  |  |  |
| --- | --- | --- |
|  | **Placebo****n = 111** | **Lifitegrast****n = 220** |
|  | **OD** | **OS** | **OD** | **OS** |
| Mean (SD) logMAR BCVA\* |  |  |  |  |
| Baseline (day 0) | 0.089 (0.1491) | 0.085 (0.1279) | 0.066 (0.1259) | 0.068 (0.1458) |
| Day 360 | 0.063 (0.1275) | 0.067 (0.1301) | 0.066 (0.1532) | 0.071 (0.1490) |
| Mean (SD) staining† |  |  |  |  |
| Day 0 (baseline) |  |  |  |  |
| Inferior corneal  | 2.26 (0.762) | 2.32 (0.785) | 2.28 (0.813) | 2.29 (0.821) |
| Central corneal  | 0.98 (0.935) | 1.11 (1.028) | 0.91 (0.910) | 0.98 (0.919) |
| Superior corneal  | 1.48 (1.054) | 1.59 (1.108) | 1.54 (1.053) | 1.61 (1.035) |
| Change from baseline to day 360 |  |  |  |  |
| Inferior corneal  | –1.00 (1.046) | –0.92 (0.979) | –0.97 (1.038) | –0.92 (1.096) |
| Central corneal  | –0.47 (0.891) | –0.56 (0.808) | –0.41 (0.886) | –0.39 (0.932) |
| Superior corneal  | –0.70 (0.932) | –0.68 (1.050) | –0.72 (1.053) | –0.76 (1.020) |
| Mean (SD) intraocular pressure, mm Hg |  |  |  |  |
| Baseline (day –7) | 14.5 (2.95) | 14.5 (2.79) | 14.7 (2.86) | 14.8 (2.88) |
| Day 180 | 14.4 (2.88) | 14.5 (2.95) | 14.5 (2.50) | 14.6 (2.56) |
| Day 360 | 14.5 (3.10) | 14.6 (3.02) | 14.5 (2.50) | 14.7 (2.53) |

\*A logMAR BCVA change from baseline ≥0.22 was considered to be an adverse event.

†Staining was measured on a 0- to 4-point scale (0 = none; 1 = few/rare punctate lesions; 2 = discrete, countable lesions; 3 = lesions too numerous to count; not coalescent, 4 = coalescent).

BCVA, best-corrected visual acuity; OD, right eye; OS, left eye.